Related Experiment Video

Updated: May 22, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte

Maria Rosa Costanzo1, J Thomas Heywood, Barry M Massie

  • 1Midwest Heart Foundation, Edward Heart Hospital, P.O. Box 3226, Naperville, IL 60566, USA. mariarosa.costanzo@advocatehealth.com

European Journal of Heart Failure
|May 23, 2012
PubMed

Insights

Cross-linked polyelectrolyte (CLP) improved heart failure (HF) and chronic kidney disease (CKD) symptoms without altering serum potassium levels. This study suggests CLP offers clinical benefits for patients with advanced HF and CKD.

Area of Science:

  • Cardiology
  • Nephrology
  • Clinical Pharmacology

Background:

  • Heart failure (HF) and chronic kidney disease (CKD) often coexist, creating complex management challenges.
  • Patients with advanced symptomatic HF and CKD require effective treatments that do not adversely affect serum potassium levels.

Purpose of the Study:

  • To evaluate the efficacy of cross-linked polyelectrolyte (CLP) in managing serum potassium and congestion in patients with HF and CKD.
  • To assess the impact of CLP on various clinical endpoints including dyspnea, natriuretic peptide levels, functional capacity, and quality of life.

Main Methods:

  • A double-blind, randomized, parallel, placebo-controlled trial was conducted.
  • The study involved 111 patients with advanced symptomatic HF and CKD.
  • Primary endpoint was serum potassium change; secondary endpoints included weight, dyspnea, NT-proBNP, NYHA class, 6MWT, and KCCQ scores over 8 weeks.

Main Results:

  • CLP treatment did not significantly alter serum potassium levels compared to placebo.
  • Patients receiving CLP experienced greater weight loss and showed trends towards reduced dyspnea and NT-proBNP levels.
  • Significant improvements were observed in NYHA functional class, 6-minute walk test, and quality of life in the CLP group.

Conclusions:

  • Cross-linked polyelectrolyte (CLP) demonstrates beneficial clinical effects in patients with advanced symptomatic HF and CKD.
  • CLP is a promising therapeutic option for this patient population, offering improvements in congestion and functional status without compromising serum potassium homeostasis.
Abstract

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.